NASDAQ:HSIC - Henry Schein Stock Price, News, & Analysis

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Henry Schein shares split before market open on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly issued shares were issued to shareholders after the closing bell on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

Henry Schein declared that its board has approved a share buyback program on Thursday, December 13th 2018, which allows the company to buyback $400,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 3.1% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's management believes its stock is undervalued.

Henry Schein, Inc. (NASDAQ:HSIC) released its earnings results on Tuesday, November, 6th. The company reported $1.03 EPS for the quarter, beating the consensus estimate of $1.01 by $0.02. The business earned $3.28 billion during the quarter, compared to analysts' expectations of $3.37 billion. Henry Schein had a net margin of 3.00% and a return on equity of 20.40%. The business's quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the company earned $0.87 EPS. View Henry Schein's Earnings History.

Henry Schein is scheduled to release their next quarterly earnings announcement on Tuesday, February 19th 2019. View Earnings Estimates for Henry Schein.

Henry Schein updated its FY18 earnings guidance on Tuesday, November, 6th. The company provided EPS guidance of $4.06-4.14 for the period, compared to the Thomson Reuters consensus estimate of $4.12.

16 Wall Street analysts have issued 12 month price objectives for Henry Schein's stock. Their forecasts range from $66.00 to $102.00. On average, they anticipate Henry Schein's stock price to reach $85.6429 in the next year. This suggests a possible upside of 6.4% from the stock's current price. View Analyst Price Targets for Henry Schein.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 2 sell ratings, 6 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Henry Schein.

Media coverage about HSIC stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Henry Schein earned a news impact score of 1.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the immediate future.

Some companies that are related to Henry Schein include Allergan (AGN), Illumina (ILMN), Celgene (CELG), HCA Healthcare (HCA), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Humana (HUM), Regeneron Pharmaceuticals (REGN), Baxter International (BAX), Edwards Lifesciences (EW), Actelion (ALIOF), ASTELLAS PHARMA/ADR (ALPMY), ESSILOR Intl S/S (ESLOY), Centene (CNC) and Takeda Pharmaceutical (TKPYY).

Henry Schein's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc (10.67%), Longview Partners Guernsey LTD (8.92%), BlackRock Inc. (6.94%), FMR LLC (5.69%), Select Equity Group L.P. (4.08%) and Brown Brothers Harriman & Co. (3.40%). Company insiders that own Henry Schein stock include Barry J Alperin, David Mckinley, Donald J Kabat, Gerald A Benjamin, James A Harding, Lorelei Mcglynn, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy, Stanley M Bergman and Steven Paladino. View Institutional Ownership Trends for Henry Schein.

HSIC stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Mackenzie Financial Corp, Deutsche Bank AG, Alecta Pensionsforsakring Omsesidigt, Select Equity Group L.P., Brown Brothers Harriman & Co., Schroder Investment Management Group and JPMorgan Chase & Co.. Company insiders that have sold Henry Schein company stock in the last year include David Mckinley, Mark E Mlotek, Michael S Ettinger, Paul Brons, Stanley M Bergman and Steven Paladino. View Insider Buying and Selling for Henry Schein.

HSIC stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Atlanta Capital Management Co. L L C, Morgan Stanley, AXA, American Century Companies Inc., WINTON GROUP Ltd, Ancora Advisors LLC and First Trust Advisors LP. View Insider Buying and Selling for Henry Schein.

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HSIC stock can currently be purchased for approximately $80.52.

Henry Schein has a market capitalization of $12.77 billion and generates $12.46 billion in revenue each year. The company earns $406.29 million in net income (profit) each year or $3.60 on an earnings per share basis. Henry Schein employs 22,000 workers across the globe.

The official website for Henry Schein is http://www.henryschein.com.

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected]